)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Protalix BioTherapeutics
Protalix BioTherapeutics (PLX) investor relations material
Protalix BioTherapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary12 Aug, 2026
Leadership and governance
Executive team brings decades of experience in pharma, R&D, business development, and capital markets.
Board of Directors includes industry veterans with backgrounds in biotech, pharma, and finance.
Commercial portfolio and partnerships
Two approved enzyme replacement therapies: Elfabrio for Fabry disease and Elelyso for Gaucher disease, generating revenue in multiple markets.
Global partnerships with Chiesi, Pfizer, and Fiocruz support commercialization and market expansion.
Elfabrio approved in US, EU, and other markets; Elelyso approved in 23 markets.
Significant milestone payments and royalties from partners, with Elfabrio poised for 15–20% global market share.
Financial performance and outlook
Achieved profitability with $22.1M net income in H1 2026 and $53.6M total revenues YTD, driven by Elfabrio sales and milestone payments.
Cash position of $40.7M as of June 30, 2026, with no debt or warrants and 80.6M shares outstanding.
Well-capitalized to support ongoing operations and pipeline development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Protalix BioTherapeutics
- Profitable biotherapeutics innovator with strong revenue, pipeline, and global partnerships.PLX
Corporate presentation - Net income surged to $22.1M on doubled revenues and a $25M milestone, with strong outlook.PLXQ2 2026
- Commercial success and pipeline innovation drive growth in rare disease therapeutics.PLXCorporate presentation
- Q1 2026 net income hit $18.3M on a $25M milestone; 2026 guidance reaffirmed.PLXQ1 2026
- Shareholders will vote on director elections, executive pay, stock plan expansion, and auditor ratification.PLXProxy filing
- EU approval of Elfabrio's four-week dosing drives revenue growth and strengthens cash position.PLXQ4 2025
- Q3 2024 delivered 75% revenue growth, $3.2M net income, and debt elimination as PRX-115 advanced.PLXQ3 2024
- Net loss of $2.2M as revenue fell and milestone payments lapsed, but pipeline progress continued.PLXQ2 2024
- Record revenues, debt repaid, and pipeline progress set stage for future royalty growth.PLXQ4 2024
Next Protalix BioTherapeutics earnings date
Q3 202612 Nov, 2026
Protalix BioTherapeutics
Next Protalix BioTherapeutics earnings date
Q3 202612 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage